Drugs / ADU-1604
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03674502 | Nov 2018 → Aug 2019 | metastatic melanoma | Aduro Biotech, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-10-20 | Sairopa B.V. | Results Sairopa Presents Promising ADU-1604 Clinical Data at ESMO Congress 2025: Novel CTLA-4 Blocking Antibody Demonstrates Benchmark Efficacy with Improved Safety Profile in Melanoma Patients sairopa.com ↗
The poster presentation featured the full results from the SRP-21C101 Phase 1 combined dose escalation and dose expansion clinical trial. |
| 2024-06-01 | Sairopa B.V. | Results Sairopα’s anti-CTLA4 Antibody Shows Clinical Efficacy with a Mild Safety Profile sairopa.com ↗
Data from the completed dose-escalation study (n=20) in PD-1 relapsed/refractory melanoma patients shows that ADU-1604 is well tolerated at dosages of 25, 75, 225 and 450 mg Q3W, demonstrating a mild safety profile and no dose-limiting toxicities. |
| 2023-11-04 | Sairopa B.V. | Results Sairopa Presents Early Clinical Data on ADU-1604 Compound at SITC 38th Annual Meeting - Sairopa sairopa.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADU-1604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03674502 ↗ |
| Modality | Monoclonal antibody | “anti-CTLA-4 monoclonal antibody” NCT03674502 ↗ |
| Route | Intravenous | “ADU-1604 administered by IV infusion” NCT03674502 ↗ |